Get the tools used by (smart)2 investors.
SP500 0.7%DOW 0.0%FTSE 100 0.1%NIKKEI 1.9%OIL 0.8%GOLD -1.1%
Sign In
WatchlistsIdeasScreenerData ExplorerChartsSaved Work

Capital Expenditures Forecast (FINBOX) for Assertio Therapeutics Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

ASRT: Assertio Therapeutics Inc

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the tre...

0.62 USD
Price
– USD
Fair Value
–
Upside
0.51 - 1.80
52-week range
Create ChartCreate ModelAdd To Watchlist

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Assertio Therapeutics Inc's Capital Expenditures Forecast (FINBOX):

Dec 2026Dec 2028Dec 2030Dec 2032Dec 20340 K500 K1,000 K1.5 M2 M2.5 M
Performance Summary
  • Assertio Therapeutics's capital expenditures forecast for the next fiscal year is 2 million
  • Assertio Therapeutics's capital expenditures forecast is expected to average 2.094 million over the next 5 fiscal years.
  • Assertio Therapeutics's is expected to deliver median capital expenditures forecast of 2.007 million over the next 5 fiscal years.

How does Assertio Therapeutics's Capital Expenditures Forecast (FINBOX) benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Assertio Therapeutics Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Assertio Therapeutics Capital Expenditures Forecast (FINBOX) Benchmarks
NameTickerCapital Expenditures Forecast (FINBOX)
Ironwood Pharmaceuticals IncNASDAQGS:IRWD100 K
Aquestive Therapeutics IncNASDAQGM:AQST900 K
HealthcareSECTOR:HLTH.US1.103 M
Collegium Pharmaceutical IncNASDAQGS:COLL1.5 M
Assertio Therapeutics IncNASDAQCM:ASRT2 M
Supernus Pharmaceuticals IncNASDAQGM:SUPN4.25 M
Prestige Consumer Healthcare IncNYSE:PBH8.886 M
ANI Pharmaceuticals IncNASDAQGM:ANIP15 M
Pacira Pharmaceuticals IncNASDAQGS:PCRX16 M
Jazz Pharmaceuticals PLCNASDAQGS:JAZZ30 M
Amphastar PNASDAQGS:AMPH40 M
AstraZeneca PLCPINC:AZNC.F2.227 B

Metric Usage: Capital Expenditures Forecast

Hide this widget
capex_proj
Slug
number
Datatype
text
Format
current
Default Period
FY, Q
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Capital Expenditures Forecast (FINBOX) in the forecast category include:

View Full List

Search for metric or datapoint

Capital Expenditures Forecast

Projected capital expenditures.

Definition of Capital Expenditures Forecast (FINBOX)

Hide this widget
Projected capital expenditures.

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
0 K200 M400 M682.4 M05001,0001,500

The chart above depicts the distribution of capital expenditures forecast (finbox) for companies operating in the Healthcare sector in the Developed economic region. Over 2,390 companies were considered in this analysis, and 2,347 had meaningful values. The average capital expenditures forecast (finbox) of companies in the sector is 21.95 M with a standard deviation of 75.151 M.

Assertio Therapeutics Inc's Capital Expenditures Forecast (FINBOX) of 2 M ranks in the 60.9% percentile for the sector. The following table provides additional summary stats:

Capital Expenditures Forecast (FINBOX) In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,395
Included Constituents2,347
Min0 K
Max675 M
Median940.653 K
Mean21.95 M
Standard Deviation75.151 M

You can find companies with similar capital expenditures forecast (finbox) using this stock screener.

All rights reserved. Terms Of Use